Fiche publication
Date publication
juillet 2019
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S
Lien Pubmed
Résumé
Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40-50% of the patients do not respond to these treatments and severe side effects are observed in up to 60%. Therefore, there is a high need to identify reliable biomarkers predicting response. Tumor Mutation Burden (TMB) is a debated predictor for response to checkpoint inhibitors and early measurement of ctDNA can help to detect treatment failure to immunotherapy in selected melanoma patients. However, it has not yet been clarified how TMB and ctDNA can be used to estimate response to combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma.
Mots clés
Adolescent, Adult, Aged, Antineoplastic Agents, Immunological, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Biomarkers, Tumor, genetics, CTLA-4 Antigen, antagonists & inhibitors, Circulating Tumor DNA, Female, Humans, Ipilimumab, therapeutic use, Male, Melanoma, drug therapy, Middle Aged, Mutation, Nivolumab, therapeutic use, Programmed Cell Death 1 Receptor, antagonists & inhibitors, Young Adult
Référence
J Immunother Cancer. 2019 07 12;7(1):180
